| Identification | Back Directory | [Name]
SNT-207858 | [CAS]
1104080-42-3 | [Synonyms]
SNT-207858
SNT207858; SNT-207858
N-[(2R)-3-(2,4-dichlorophenyl)-1-oxo-1-[4-[3-[(2R)-2-pyrrolidin-1-ylbutoxy]pyridin-2-yl]piperidin-1-yl]propan-2-yl]pyrrolidine-1-carboxamide
N-[(2R)-3-(2,4-dichlorophenyl)-1-oxo-1-[4-[3-[(2R)-2-pyrrolidin-1-ylbutoxy]pyridin-2-yl]piperidin-1-yl]propan-2-yl]pyrrolidine-1-carboxamide:dihydrochloride
1-PyrrolidinecarboxaMide, N-[(1R)-1-[(2,4-dichlorophenyl)Methyl]-2-oxo-2-[4-[3-[(2R)-2-(1-pyrrolidinyl)butoxy]-2-pyridinyl]-1-piperidinyl]ethyl]-, hydrochloride (1:2) | [Molecular Formula]
C32H45Cl4N5O3 | [MDL Number]
MFCD20526445 | [MOL File]
1104080-42-3.mol | [Molecular Weight]
653.09 |
| Hazard Information | Back Directory | [Uses]
SNT-207858 is used in pharmacological studies and is a melanocortin-4 receptor antagonist with antiemetic effect and is used with other agents.Has antidiabetic agents. | [in vivo]
SNT207858 (30 mg/kg; oral administration; once daily; 15 days) significantly reduces the tumor induced weight loss in mice[1]. | Animal Model: | Mice with C26 adenocarcinoma-induced cachexia model[1] | | Dosage: | 30 mg/kg | | Administration: | Oral administration; once daily; 15 days | | Result: | Significantly reduced the tumor induced weight loss. |
| [storage]
Store at -20°C |
|
|